ALCAM Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated

Catalog No. TMPK-00341 Copy Product Info

Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM. ALCAM Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 57 kDa and the accession number is Q13740-1.

ALCAM Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated

Catalog No. TMPK-00341

Copy Product Info

ALCAM Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated

Pack Size	Price	USA Stock	Global Stock
5 μg	$91	7-10 days	7-10 days
10 μg	$148	7-10 days	7-10 days
20 μg	$245	7-10 days	7-10 days
50 μg	$483	7-10 days	7-10 days
100 μg	$813	7-10 days	7-10 days
200 μg	$1,470	7-10 days	7-10 days
500 μg	$3,250	7-10 days	7-10 days

Add to Cart

Add to Quotation

In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Resource Download

User Guide of Recombinant Proteins

Product Information

Biological Activity	Immobilized Anti-ALCAM Antibody, hFc Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human ALCAM, His Tag with the EC50 of 1.6μg/ml determined by ELISA.
Description	Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM. ALCAM Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 57 kDa and the accession number is Q13740-1.
Species	Human
Expression System	HEK293 Cells
Tag	C-His
Accession Number	Q13740-1
Synonyms	MEMD,KG-CAM,CD6L,CD166,ALCAM
Construction	Trp28-Ala526
Protein Purity	> 95% as determined by Tris-Bis PAGE
Molecular Weight	57 kDa (predicted). Due to glycosylation, the protein migrates to 70-80 kDa based on Tris-Bis PAGE result.
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Research Background	Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM.